GlassScriptPhysician profile
Peter G Gourley
NPI 1114961240
$4,691.85
in general payments reported to CMS, 2019-2025
19 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $997 · 2023: $1,355 · 2024: $276 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462 · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.77 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $744.34 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $440.73 | 2021-2025 | Ingrezza |
| Abbvie INC. | $398.79 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $376.26 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $346.19 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $299.91 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $294.47 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $286.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $281.54 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $264.14 | 2021-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $254.25 | 2022-2025 | Rexulti |
| Corium, LLC | $218.16 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $197.11 | 2022-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $123.86 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $54.16 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.58 | 2025 | Trintellix |
| Lilly USA, LLC | $20.72 | 2025 | Zepbound |
| Indivior INC. | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gourley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.